More Than 125 Customers Worldwide Live on Vault CRM as Veeva Accelerates the Industry's Agentic Transformation
Veeva (NYSE: VEEV) announced that more than 125 customers are live on Vault CRM across the U.S., Europe and Japan, including multiple top‑20 biopharma companies.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Veeva (NYSE: VEEV) announced that more than 125 customers are live on Vault CRM across the U.S., Europe and Japan, including multiple top‑20 biopharma companies. With the availability of Veeva AI, Veeva says it is accelerating the industry's shift to agentic CRM.
Veeva updated the end‑of‑support date for legacy Veeva CRM from September 2030 to end of December 2029. Vault CRM is part of the Vault CRM Suite, which also includes Events Management, Service Center, Campaign Manager, and Patient CRM.
Positive
- More than 125 customers live on Vault CRM
- Global adoption across U.S., Europe, and Japan including top‑20 biopharma
- Availability of Veeva AI to accelerate agentic CRM adoption
Negative
- End‑of‑support for legacy Veeva CRM moved earlier to Dec 2029
Details
News Market Reaction – VEEV
On Mar 3, the day this news came out, VEEV closed 2.46% above the previous close.
Data tracked by StockTitan Argus for the Mar 3 session.
Key Figures
- Vault CRM customers
- more than 125 customers
- Number of customers live on Veeva Vault CRM worldwide
- Top biopharmas cohort
- top 20 biopharmas
- Vault CRM customers include multiple top 20 biopharmas
- Regions covered
- U.S., Europe, Japan
- Key regions where Vault CRM customers are live
- Prior end-of-support
- September 2030
- Original end-of-support date for Veeva CRM
- Updated end-of-support
- end of December 2029
- New end-of-support date for Veeva CRM
Historical Context
-
Announced March 4, 2026 date for Q4 and full-year fiscal 2026 results.
-
Reported 13 of top 20 biopharmas standardized on Veeva Link Key People.
-
Announced Veeva eSource to eliminate paper and streamline clinical trial data flow.
-
Highlighted State of AI in Consumer Goods report on AI-readiness priorities.
-
Disclosed upcoming presentation at the J.P. Morgan 2026 Healthcare Conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
With broad industry success and the availability of Veeva AI, Vault CRM is the leader in agentic CRM for life sciences
The strong momentum behind Vault CRM reflects the clear business value of its deep industry and regional functionality, compliance, workflows, and agents. Vault CRM provides the foundation commercial and medical teams require to support the full product lifecycle and complex customer engagements, from initial market preparation and launches to optimizing the performance of mature brands.
"More than 125 customers are already live with Vault CRM and on the fast path to agentic customer engagement," said Arno Sosna, president, CRM Suite, Veeva. "We're expanding that impact across the industry as we lead with a focus on customer success and product excellence."
With the success of Vault CRM and a well-established upgrade path, Veeva has updated the end-of-support date for Veeva CRM from September 2030 to the end of December 2029.
Vault CRM is part of the Vault CRM Suite of applications that provide the technology foundation for commercial execution for biopharma companies of all sizes in all regions. Vault CRM Suite also includes Events Management, Service Center, Campaign Manager, and Patient CRM.
About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.
Contact: | |
Maria Scurry |
View original content to download multimedia:https://www.prnewswire.com/news-releases/more-than-125-customers-worldwide-live-on-vault-crm-as-veeva-accelerates-the-industrys-agentic-transformation-302701782.html
SOURCE Veeva Systems
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.